Home > Insider Trading > Filing (0001179110-11-015315)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1145460	Alere Inc.	ALR	In Vitro & In Vivo Diagnostic Substances (2835)	043565120

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1272540	Hilde Eylenbosch	51 Sawyer Road, Suite 200 Waltham 02453	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-11-15	17,229	$15.47	47,365	No	4	M	Direct
Common Stock	Disposition	2011-11-15	17,229	$26.02	30,136	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2011-11-15	17,229	$0.00	17,229	$15.47

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2011-11-30	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	43,143	Indirect	Spouse
Common Stock	3,248	Direct

Footnotes

These options became exercisable in four equal annual installments beginning 11/30/2002.
This derivative security does not have a price.
This reporting person disclaims beneficial ownership of the reported securities.
These securities are jointly owned with the reporting person's spouse.
Represents the weighted average purchase price. Securities were sold through approximately 114 separate block trades executed on the Transaction Date at an average price of $26.024. The reporting person hereby undertakes to provide upon request to the SEC, the issuer or any stockholder of the issuer the full information regarding the number of shares and prices at which the transaction was effected.
The transactions reported on this Form were made pursuant to a written 10b5-1 trading plan adopted in accordance with SEC Rule 10b5-1. Represents same day exercise and sale of expiring stock options.